Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab SC vs IV in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT05405166Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Started Jun 2022; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05405166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405166.